,

Rev Esp Quimioter 2024, 37(4): 341-350

Progression of subclinical cardiovascular disease in patients with HIV

MARINA FAYOS, FRANCISCO ARNAIZ DE LAS REVILLAS, VICENTE GONZÁLEZ QUINTANILLA, CLAUDIA GONZÁLEZ-RICO, CONCEPCIÓN FARIÑAS-ÁLVAREZ, JOSÉ ANTONIO PARRA, MARÍA CARMEN FARIÑAS

Published: 29 April 2024

http://www.doi.org/10.37201/req/033.2024

Introduction. Human immunodeficiency virus (HIV) infected patients are at increased risk of cardiovascular disease (CVD). Multidetector computed tomography (MDCT) stratifies cardiovascular risk in asymptomatic patients with subclinical atherosclerosis. The aim of this study was to determine the ability of MCTD and clinical and laboratory parameters to assess subclinical CVD progression in HIV patients.
Material and methods. Prospective longitudinal cohort study of patients with at least 10 years of HIV infection and 5 years of antiretroviral therapy history, low cardiovascular risk and monitored for 6 years (2015–2021). All patients underwent clinical assessment, blood analysis, carotid ultrasound, and gated MDCT in 2015 and 2021.
Results. Sixty-three patients (63.5% male) with a mean age of 49.9 years (standard deviation [SD], 10.5) were included in 2015; 63 of them were followed until 2021. Comparing the results from 2015 with those from 2021, Systematic Coronary Risk Estimation-2 (SCORE2) was 2.9% (SD, 2.1) vs. 4.4% (SD,3.1); Multi-Ethnic Study of Atherosclerosis score (MESA risk) was 3.4 (SD 5.8) vs. 6.0 (SD 8.6); coronary artery calcification CAC) score >100 was 11.1% vs. 25.4% (P < 0.05); and 11% vs. 27% had carotid plaques (P = 0.03).
Conclusions. After six years of follow-up, an increase in SCORE2, carotid plaques, CAC scoring and MESA risk was observed. MDCT findings, along with other clinical and laboratory parameters, could play an important role as a marker of CVD progression in the evaluation of patients with HIV and low cardiovascular risk.

Rev Esp Quimioter 2024; 37(4): 341-350 [Full-text PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 283-284

Glecaprevir/pibrentasvir en combinación con ribavirina como terapia de rescate en hepatitis C crónica

MARÍA DEL MAR SÁNCHEZ SUÁREZ, ALICIA MARTÍN ROLDÁN, MARÍA ROSA CANTUDO CUENCA

Published: 19 April 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/020.2024

Rev Esp Quimioter 2024; 37(3): 283-284 [Texto completo PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 281-282

Artritis séptica por Pasteurella multocida

CARMEN PIÑA DELGADO, MARÍA NIEVES CARMONA TELLO, MARGARITA BOLAÑOS RIVERO, MARÍA DEL CARMEN LAVILLA SALGADO, ISABEL DE MIGUEL MARTÍNEZ

Published: 17 April 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/019.2024

Rev Esp Quimioter 2024; 37(3): 281-282 [Texto completo PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 252-256

The role of viral diagnostic tests in respiratory tract infections: moving forward

RAÚL ORTÍZ DE LEJARAZU, JOSÉ M. EIROS, FRANCISCO LÓPEZ-MEDRANO, MILAGROS MONTES, ALFREDO TAGARRO, MARÍA TOMÁS

Published: 12 April 2024

http://www.doi.org/10.37201/req/150.2023

The increased knowledge on virology and the increased potential of their diagnostic has risen several relevant question about the role of an early viral diagnosis and potential early treatment on the management of respiratory tract infections (RTI). In order to further understand the role of viral diagnostic tests in the management of RTI, a panel of experts was convened to discuss about their potential role, beyond what had been agreed in Influenza. The objective of this panel was to define the plausible role of aetiologic viral diagnostic into clinical management; make recommendations on the potential expanded use of such tests in the future and define some gaps in the management of RTI. Molecular Infection Viral Diagnostic (mIVD) tests should be used in all adult patients admitted to Hospital with RTI, and in paediatric patients requiring admission or who would be referred to another hospital for more specialised care. The increased use of mIVD will not only reduce the inappropriate use of antibiotics so reducing the antibiotic microbe resistance, but also will improve the outcome of the patient if an aetiologic viral therapy can be warranted, saving resource requirements and improving patient flows. Implementing IVD testing in RTI has various organizational benefits as well, but expanding its use into clinical settings would need a cost-effectiveness strategy and budget impact assessment.

Rev Esp Quimioter 2024; 37(3): 252-256 [Full-text PDF] [Supplementary material PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 266-269

Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria

ABRAR SENHAJI-KACHA, ARIJ AKIR, ANTONIO BRONCANO-LAVADO, JAIME ESTEBAN

Published: 11 April 2024

http://www.doi.org/10.37201/req/014.2024

Introduction. Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment.
Methods. Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM.
Results. In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L.
Conclusions. These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.

Rev Esp Quimioter 2024; 37(3): 266-269 [Full-text PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 274-275

Endocarditis infecciosa por Listeria monocytogenes: Caso tratado sin intervención quirúrgica con adecuada evolución clínica

TELMO FERNANDEZ DE CASADEVANTE, XABIER CAMINO, AINHOA ARTECHE, ANA ALONSO, PAUL MARTINAGE

Published: 10 April 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/141.2023

Rev Esp Quimioter 2024; 37(3): 274-275 [Texto completo PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 270-273

Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain

LUCÍA FRAILE GARCÍA, JESÚS ARAMBURU ARNUELOS, ÉRIC LÓPEZ GONZÁLEZ, ALBA BELLÉS-BELLÉS, ALBA MUÑOZ SANTA, ELENA SÁNCHEZ BÁSCONES, SARAY MORMENEO BAYO, ALBERT BERNET SÁNCHEZ, IVÁN PRATS SÁNCHEZ, ALEJANDRO CUMPLIDO PORTILLO, MERCÈ GARCÍA GONZÁLEZ

Published: 9 April 2024

http://www.doi.org/10.37201/req/015.2024

Introduction. Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area.
Material and methods. A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG & AziR Assay and AllplexTM MG & MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene.
Results. A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%).
Conclusions. The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.

Rev Esp Quimioter 2024; 37(3): 270-273 [Full-text PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 279-280

Diagnóstico rápido de un caso de meningitis posquirúrgica con BioFire® Joint Infection Panel

BELÉN CUADRADO GARCÍA, ANA MADUEÑO ALONSO, ANA MARTÍN BERMÚDEZ, LUCÍA ROMERO-ACEVEDO, PAULA PÉREZ ORÁN, MARÍA LECUONA FERNÁNDEZ

Published: 27 March 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/009.2024

Rev Esp Quimioter 2024; 37(3): 279-280 [Texto completo PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 276-278

Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review

MIGUEL CAMARA-RODRIGUEZ, FRANCISCO JOVER-DIAZ, ELISABET DELGADO-SÁNCHEZ, ANA INFANTE-URRÍOS, JORGE PERIS-GARCÍA

Published: 27 March 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/149.2023

Rev Esp Quimioter 2024; 37(3): 276-278 [Full-text PDF]


</a

/por
,

Rev Esp Quimioter 2024; 37(3): 257-265

Usefulness of the MPB-INFURG-SEMES model to predict bacteremia in the patient with solid tumor in the Emergency Department

MARÍA MUELAS GONZÁLEZ, ELENA TORNER MARCHESI, GABRIELA PELÁEZ DÍAZ, MARTA RAMOS ARANGUEZ, JAVIER CABAÑAS MORAFRAILE, WILLIAM LÓPEZ FORERO, RAFAEL RUBIO DÍAZ, JUAN GONZÁLEZ DEL CASTILLO, FRANCISCO JAVIER CANDEL, AGUSTÍN JULIÁN-JIMÉNEZ, EN NOMBRE DEL GRUPO INFURG SEMES

Published: 23 March 2024

http://www.doi.org/10.37201/req/004.2024

Objective. To analyse a new risk score to predict bacteremia (MPB-INFURG-SEMES) in the patients with solid tumor attender for infection in the emergency departments (ED).
Patients and methods. Prospective, multicenter observational cohort study of blood cultures (BC) obtained from adult patients with solid neoplasia treated in 63 EDs for infection from November 1, 2019, to March 31, 2020. The predictive ability of the model was analyzed with the area under the Receiver Operating Characteristic curve (AUC-ROC). The prognostic performance for true bacteremia was calculated with the chosen cut-off for getting the sensitivity, specificity, positive predictive value and negative predictive value.
Results. A total of 857 blood samples wered cultured. True cases of bacteremia were confirmed in 196 (22.9%). The remaining 661 cultures (77.1%) wered negative. And, 42 (4.9%) were judged to be contaminated. The model’s area under the receiver operating characteristic curve was 0.923 (95% CI,0.896-0.950). The prognostic performance with a model’s cut-off value of ≥ 5 points achieved 95.74% (95% CI, 94,92-96.56) sensitivity, 76.06% (95% CI, 75.24-76.88) specificity, 53.42%(95% CI, 52.60-54.24) positive predictive value and 98.48% (95% CI, 97.66- 99.30) negative predictive value.
Conclusion. The MPB-INFURG-SEMES score is useful for predicting bacteremia in the adults patients with solid tumor seen in the ED.

Rev Esp Quimioter 2024; 37(3): 257-265 [Texto completo PDF]


</a

/por